SAN DIEGO – An experimental pill from Eli Lilly led to 14.7% weight loss at the highest dose in a 36-week trial, fueling growing competition among drug makers to develop an effective oral obesity therapy.
The mid-stage results for orforglipron are consistent with estimates of 14-15% weight loss that Lilly gave in an investor call late last year. The complete Results, published Friday in the New England Journal of Medicine, were presented here to a packed conference room at the conference of the American Diabetes Association.
By the end of the trial, the authors said, the participants’ weight loss had not leveled off, suggesting possible even greater weight loss over a longer treatment period.